177 related articles for article (PubMed ID: 32991164)
1. Benzylguanidine and Galactose Double-Conjugated Chitosan Nanoparticles with Reduction Responsiveness for Targeted Delivery of Doxorubicin to CXCR 4 Positive Tumors.
Kong F; Tang C; Yin C
Bioconjug Chem; 2020 Oct; 31(10):2446-2455. PubMed ID: 32991164
[TBL] [Abstract][Full Text] [Related]
2. Dual-targeting nanoparticles with core-crosslinked and pH/redox-bioresponsive properties for enhanced intracellular drug delivery.
Zhao J; Yan C; Chen Z; Liu J; Song H; Wang W; Liu J; Yang N; Zhao Y; Chen L
J Colloid Interface Sci; 2019 Mar; 540():66-77. PubMed ID: 30634060
[TBL] [Abstract][Full Text] [Related]
3. Bromelain-decorated hybrid nanoparticles based on lactobionic acid-conjugated chitosan for in vitro anti-tumor study.
Wei B; He L; Wang X; Yan GQ; Wang J; Tang R
J Biomater Appl; 2017 Aug; 32(2):206-218. PubMed ID: 28618976
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles.
Wang X; Zhen X; Wang J; Zhang J; Wu W; Jiang X
Biomaterials; 2013 Jun; 34(19):4667-79. PubMed ID: 23537667
[TBL] [Abstract][Full Text] [Related]
5. Stepwise pH-responsive nanoparticles for enhanced cellular uptake and on-demand intracellular release of doxorubicin.
Chen WL; Li F; Tang Y; Yang SD; Li JZ; Yuan ZQ; Liu Y; Zhou XF; Liu C; Zhang XN
Int J Nanomedicine; 2017; 12():4241-4256. PubMed ID: 28652730
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
Zeng X; Morgenstern R; Nyström AM
Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
Li W; Yi X; Liu X; Zhang Z; Fu Y; Gong T
J Control Release; 2016 Mar; 225():170-82. PubMed ID: 26826304
[TBL] [Abstract][Full Text] [Related]
8. Dual-targeting and pH/redox-responsive multi-layered nanocomplexes for smart co-delivery of doxorubicin and siRNA.
Han L; Tang C; Yin C
Biomaterials; 2015 Aug; 60():42-52. PubMed ID: 25982552
[TBL] [Abstract][Full Text] [Related]
9. Biotin-Conjugated Multilayer Poly [D,L-lactide-co-glycolide]-Lecithin-Polyethylene Glycol Nanoparticles for Targeted Delivery of Doxorubicin.
Dai Y; Xing H; Song F; Yang Y; Qiu Z; Lu X; Liu Q; Ren S; Chen X; Li N
J Pharm Sci; 2016 Sep; 105(9):2949-2958. PubMed ID: 27209461
[TBL] [Abstract][Full Text] [Related]
10. Bile acid-conjugated chondroitin sulfate A-based nanoparticles for tumor-targeted anticancer drug delivery.
Lee JY; Chung SJ; Cho HJ; Kim DD
Eur J Pharm Biopharm; 2015 Aug; 94():532-41. PubMed ID: 26149228
[TBL] [Abstract][Full Text] [Related]
11. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.
Qiu R; Sun D; Bai Y; Li J; Wang L
Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
[TBL] [Abstract][Full Text] [Related]
13. Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma.
Xia Y; Zhong J; Zhao M; Tang Y; Han N; Hua L; Xu T; Wang C; Zhu B
Drug Deliv; 2019 Dec; 26(1):1-11. PubMed ID: 31928356
[TBL] [Abstract][Full Text] [Related]
14.
El-Ghareb WI; Swidan MM; Ibrahim IT; Abd El-Bary A; Tadros MI; Sakr TM
Int J Pharm; 2020 Aug; 586():119514. PubMed ID: 32565281
[TBL] [Abstract][Full Text] [Related]
15. Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy.
Misra R; Sahoo SK
Eur J Pharm Sci; 2010 Jan; 39(1-3):152-63. PubMed ID: 19961929
[TBL] [Abstract][Full Text] [Related]
16. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
[TBL] [Abstract][Full Text] [Related]
17. Chemosensitizing indomethacin-conjugated chitosan oligosaccharide nanoparticles for tumor-targeted drug delivery.
Lee JY; Termsarasab U; Lee MY; Kim DH; Lee SY; Kim JS; Cho HJ; Kim DD
Acta Biomater; 2017 Jul; 57():262-273. PubMed ID: 28483700
[TBL] [Abstract][Full Text] [Related]
18. Novel, Self-Distinguished, Dual Stimulus-Responsive Therapeutic Nanoplatform for Intracellular On-Demand Drug Release.
Sun H; Fan Z; Xiang S; Zuo W; Yang Y; Huang D; Su G; Fu X; Zhao Q; Hou Z
Mol Pharm; 2020 Jul; 17(7):2435-2450. PubMed ID: 32459486
[TBL] [Abstract][Full Text] [Related]
19. The chemotherapeutic potential of doxorubicin-loaded PEG-b-PLGA nanopolymersomes in mouse breast cancer model.
Alibolandi M; Sadeghi F; Abnous K; Atyabi F; Ramezani M; Hadizadeh F
Eur J Pharm Biopharm; 2015 Aug; 94():521-31. PubMed ID: 26170161
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of doxorubicin and siRNA by all-trans retinoic acid conjugated chitosan-based nanocarriers for multiple synergistic antitumor efficacy.
Liu C; Tang C; Yin C
Carbohydr Polym; 2022 May; 283():119097. PubMed ID: 35153031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]